Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309:(19)2005-2015

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 [published correction appears in Arch Ophthalmol. 2008;126(9):1251]. Arch Ophthalmol. 2001; 119:(10)1417-1436

Burton MJ, Ramke J, Marques AP The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021; 9:(4)e489-e551

Chakravarthy U, Bailey CC, Scanlon PH Progression from early/intermediate to advanced forms of age-related macular degeneration in a large UK cohort: rates and risk factors. Ophthalmol Retina. 2020; 4:(7)662-672

Fernandes AR, Zielińska A, Sanchez-Lopez E Exudative versus nonexudative age-related macular degeneration: physiopathology and treatment options. Int J Mol Sci. 2022; 23:(5)

Fleckenstein M, Keenan TDL, Guymer RH Age-related macular degeneration. Nat Rev Dis Primers. 2021; 7:(1)

Greenwood V, Stanford P, Beddow C, Bowen M, Hingorani M. Changing practice for the non-medical ophthalmic hospital workforce in the UK-a snapshot survey. Eye (Lond). 2021; 35:(7)1886-1894

Wet age-related macular degeneration (Wet AMD) [Updated 2022 Nov 7]. 2023. (accessed 7 September 2023)

Llewellyn M, Hilgart J, Joshi P Impact of eye clinic liaison officers: a qualitative study in UK ophthalmology clinics. BMJ Open. 2019; 9

LoBue SA, Gindina S, Saba NJ, Chang T, Davis MJ, Fish S. Clinical features associated with acute elevated intraocular pressure after intravitreal anti-vegf injections. Clin Ophthalmol. 2023; 17:1683-1690

Lombardo M, Serrao S, Lombardo G. Challenges in age-related macular degeneration: from risk factors to novel diagnostics and prevention strategies. Front Med (Lausanne). 2022; 9

National Institute of Health and care Excellence. Age-related macular degeneration. 2018. (accessed 29 August 2023)

NHS England. Getting it right first time. Ophthalmic Pathway. Age-related macular degeneration (AMD). 2023. (accessed 29 August 2023)

Rahman F, Zekite A, Bunce C Recent trends in vision impairment certifications in England and Wales. Eye. 2020; 34:1271-1278

Royal College of Ophthalmologists. National ophthalmology database audit: the first report of age-related macular degeneration audit (AMD). Patients starting treatment for neovascular AMD in the 2020 NHS year (01 April 2020 to 31 March 2021). 2023. (accessed 29 August 2023)

Scheffer M, Menting J, Roodbeen R Patients' and health professionals' views on shared decision-making in age-related macular degeneration care: a qualitative study. Ophthalmic Physiol Opt. 2022; 42:(5)1015-1022

Stanford P, Waterman H, Russell WB, Harper RA. Psychosocial adjustment in age related macular degeneration. British Journal of Visual Impairment. 2009; 27:(2)129-146

Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR. Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options. Clin Ophthalmol. 2022; 16:917-933

Thier A, Holmberg C. The patients' view: age-related macular degeneration and its effects—a meta-synthesis. Disabil Rehabil. 2022; 44:(5)661-671

Amsler grid. 2023. (accessed 7 September 2023)

UK Government. Stop the rot: new campaign highlights how cigarettes ‘rot’ the body from the inside. 2014. (accessed 5 September 2023)

World Health Organization. World Report on Vision. 2019. (accessed 29 August 2023)

World Health Organization. Blindness and visual impairment factsheet. 2023. (accessed 29 August 2023)

Age-related macular degeneration: care of the patient in the community setting

02 October 2023
Volume 28 · Issue 10


The aim of this article is to explain age-related macular degeneration (AMD) and how it impacts on the wellbeing of patients in the community setting. It explores the anatomy and physiology associated with AMD, its symptoms and treatment, and goes on to discuss related nursing care.

Many eye diseases are likely to affect the visual pathway and in age-related macular degeneration (AMD) this involves the neurosensory retina. AMD is a degenerative eye disease that causes loss of central vision. There are two main types of AMD—wet and dry. AMD causes painless loss of vision and predominantly affects older people, although other age groups may develop macular degeneration (MD). Visual impairment can have negative consequences on a person's health and wellbeing. Ageing and the ageing population are inevitably linked to age-related eye disorders and the likelihood of visual impairment (WHO, 2023). Current data estimates that visual impairment affects 2.2 billion people across the world (WHO, 2019), and AMD is one of the leading global causes of visual impairment (Burton et al, 2021).

The literature provides consensus on the structure and function of the anatomy and physiology related to AMD (Batterbury and Murphy, 2018; Kanski, 2019). The relationship between the normal anatomy of the eye and pathological changes that occur in some diseases such as AMD, has inevitable consequences on vision. The physiological function of the eye is to convert light from images into electrical impulses, which are then interpreted by the brain as vision. The retina—the inner transparent layer of the eye—is a neurosensory layer. Photoreceptors present in the retina, specifically on the macular, known as rods and cones, are essential in this process. The macula is an area on the retina that facilitates central vision. The fovea, located at the centre of the macula—this is the part of the eye. Its adjective is macular eg macular degeneration. This author confuses the two oftenr, is responsible for detailed vision. Macular rods and cones are more concentrated on the macular responsible for colour and acute central vision. Rods are also present throughout the retina, mostly in the peripheral retina and aid perception of movement and facilitate vision in low light conditions.

Register now to continue reading

Thank you for visiting Community Nursing and reading some of our peer-reviewed resources for district and community nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month